End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
760 MXN | +4.11% | +9.35% | -12.39% |
01:37pm | ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial | MT |
06-07 | Geron shares surge after U.S. FDA approves blood disorder drug | RE |
Sales 2024 * | 46.09B 843B 63.42B | Sales 2025 * | 46.06B 842B 63.38B | Capitalization | 84.08B 1,537B 116B |
---|---|---|---|---|---|
Net income 2024 * | -5.41B -98.99B -7.45B | Net income 2025 * | 10.22B 187B 14.06B | EV / Sales 2024 * | 2.67 x |
Net Debt 2024 * | 39.03B 714B 53.72B | Net Debt 2025 * | 31.68B 579B 43.59B | EV / Sales 2025 * | 2.51 x |
P/E ratio 2024 * |
-15.8
x | P/E ratio 2025 * |
7.85
x | Employees | 34,100 |
Yield 2024 * |
5.8% | Yield 2025 * |
6.09% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
1 day | +4.11% | ||
1 week | +9.35% | ||
Current month | +9.35% | ||
1 month | +1.86% | ||
3 months | -16.16% | ||
6 months | -13.38% | ||
Current year | -12.39% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 760 | +4.11% | 12,999 |
24-06-06 | 730 | +0.83% | 760 |
24-06-05 | 724 | -2.82% | 235 |
24-06-04 | 745 | +2.05% | 6,614 |
24-06-03 | 730 | +5.04% | 24 |
End-of-day quote Mexican S.E., June 06, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.39% | 765B | |
-6.13% | 354B | |
+20.61% | 331B | |
+10.00% | 299B | |
+18.87% | 248B | |
-1.96% | 219B | |
+11.11% | 216B | |
+5.80% | 164B | |
-2.50% | 162B |
- Stock Market
- Equities
- BMY Stock
- BMY * Stock